<DOC>
	<DOCNO>NCT02519114</DOCNO>
	<brief_summary>The aim phase 2 study demonstrate KIR-ligand mismatch haploBMT post-transplant cyclophosphamide improve progression free survival poor risk multiple myeloma patient .</brief_summary>
	<brief_title>Haploidentical Bone Marrow Stem Cell Transplantation Patients With Multiple Myeloma</brief_title>
	<detailed_description>The goal study evaluate effectiveness new treatment modality , KIR-ligand mismatch haploidentical stem cell transplantation ( haploBMT ) , poor risk multiple myeloma ( MM ) patient . MM malignancy plasma cell usually reside bone marrow . Despite new treatment modality introduce last year , MM still incurable disease patient median survival young patient ( &lt; 65 ) 5 year . MM treat several disease modifier - classical chemotherapy , high dose chemotherapy autologous stem cell transplantation ( ASCT ) , immunomodulators like thalidomide lenalidomide , drug like bortezomib interact relevant intracellular pathway malignant plasma cell . Though treatment modality improve overall survival quality life , patient cure .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Patients MM &lt; 60 year . Poor prognosis MM patient , permissive KIRligand mismatch KIRligand mismatch haploidentical donor . Poor prognosis base : Patients early disease recurrence ( within 12 month first ASCT ) Patients minimum three line chemotherapy ( include high dose therapy follow ASCT rescue therapy ) Poor risk base cytogenetic profile . Written inform consent No HLA identical relate 10/10 match unrelated donor Permissive KIRligand mismatch Responsive reinduction therapy Measurable disease Patients full match ( 10/10 ) donor , enroll HOVON 96 study Active uncontrolled infection Uncontrolled CNS involvement malignant disease Severe cardiovascular disease ( arrhythmias require chronic treatment , congestive heart failure symptomatic ischemic heart disease ) Severe pulmonary dysfunction ( CTCAE grade IIIIV ) Severe neurological psychiatric disease Significant hepatic dysfunction ( serum bilirubin transaminase â‰¥ 3 time upper limit normal ) Significant renal dysfunction ( creatinine clearance &lt; 30 ml/min rehydration ) History active malignancy past 5 year exception basal carcinoma skin stage 0 cervical carcinoma Any psychological , familial , lingual , sociological geographical condition potentially hamper compliance study protocol followup schedule Breastfeeding female patient . Concurrent severe and/or uncontrolled medical condition ( DM , hypertension , cancer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>M Myeloma</keyword>
	<keyword>KIR ligand mismatch</keyword>
	<keyword>Haploidentical</keyword>
</DOC>